Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bob T Li

Showing results (51-60 of 139) with videos related to

Pageof 14
Sort By:
The Journal of Molecular Diagnostics : JMD|December 26, 2021
Multiplex SuperSelective PCR Assays for the Detection and Quantitation of Rare Somatic Mutations in Liquid BiopsiesDiana Y Vargas, Sanjay Tyagi, Salvatore A E Marras, et al.
Cancer Discovery|March 28, 2020
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid TumorsJunji Tsurutani, Hiroji Iwata, Ian Krop, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung CancersMichael Offin, Hira Rizvi, Megan Tenet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2018
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of ResistanceHelena A Yu, Ken Suzawa, Emmet Jordan, et al.
JTO Clinical and Research Reports|December 21, 2023
Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLCBrandon S Imber, Ryka Sehgal, Rachel Saganty, et al.
Cell Reports. Medicine|October 22, 2024
EGFR-directed antibodies promote HER2 ADC internalization and efficacyAvantika Gupta, Flavia Michelini, Hong Shao, et al.
JCO Precision Oncology|September 14, 2020
CNS Metastases in Patients With <i>MET</i> Exon 14-Altered Lung Cancers and Outcomes With CrizotinibMichael Offin, Jia Luo, Robin Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2019
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable AlterationsSiddhartha Devarakonda, Sumithra Sankararaman, Brett H Herzog, et al.
Targeted Oncology|November 2, 2024
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib TrialErika P Hamilton, Gerald S Falchook, Judy S Wang, et al.
International Journal of Radiation Oncology, Biology, Physics|February 10, 2025
Intracranial Disease Control and Survival among Patients with KRAS-mutant Lung Adenocarcinoma and Brain Metastases Treated with Stereotactic RadiosurgeryBenjamin Gaeta, Jordan E Eichholz, Henry Walch, et al.
Pageof 14

Showing results (51-60 of 139) with videos related to

Sort By:
Pageof 14
The Journal of Molecular Diagnostics : JMD|December 26, 2021
Multiplex SuperSelective PCR Assays for the Detection and Quantitation of Rare Somatic Mutations in Liquid BiopsiesDiana Y Vargas, Sanjay Tyagi, Salvatore A E Marras, et al.
Cancer Discovery|March 28, 2020
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid TumorsJunji Tsurutani, Hiroji Iwata, Ian Krop, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with <i>EGFR</i>-Mutant Lung CancersMichael Offin, Hira Rizvi, Megan Tenet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2018
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of ResistanceHelena A Yu, Ken Suzawa, Emmet Jordan, et al.
JTO Clinical and Research Reports|December 21, 2023
Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLCBrandon S Imber, Ryka Sehgal, Rachel Saganty, et al.
Cell Reports. Medicine|October 22, 2024
EGFR-directed antibodies promote HER2 ADC internalization and efficacyAvantika Gupta, Flavia Michelini, Hong Shao, et al.
JCO Precision Oncology|September 14, 2020
CNS Metastases in Patients With <i>MET</i> Exon 14-Altered Lung Cancers and Outcomes With CrizotinibMichael Offin, Jia Luo, Robin Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2019
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable AlterationsSiddhartha Devarakonda, Sumithra Sankararaman, Brett H Herzog, et al.
Targeted Oncology|November 2, 2024
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib TrialErika P Hamilton, Gerald S Falchook, Judy S Wang, et al.
International Journal of Radiation Oncology, Biology, Physics|February 10, 2025
Intracranial Disease Control and Survival among Patients with KRAS-mutant Lung Adenocarcinoma and Brain Metastases Treated with Stereotactic RadiosurgeryBenjamin Gaeta, Jordan E Eichholz, Henry Walch, et al.
Pageof 14